


Express Mail Label No.: EL548 626 398US		Certificate of Mailing by "Express Mail"	Date of Deposit: August 1, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231			
Dated: 8/1/01.	Name:  Edgar Benavides		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Charles A. Nicolette

Assignee: Genzyme Corp.

Filing Date: Herewith

Examiner: Unassigned

Serial No.: Unassigned

Group Art Unit: Unassigned

Title: MELANOMA ANTIGENIC PEPTIDES

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the subject divisional application, consideration and entry of the following amendments are respectfully requested.

IN THE SPECIFICATION

Page 1, lines 3 to 5, please replace this paragraph with the following rewritten paragraph.

This application is a divisional of U.S. Serial No. 09/249,272, filed February 11, 1999, now U.S. Patent No. _____, issued _____, which in turn claims priority under 35 U.S.C. § 119(e) of U.S. provisional U.S. Application No. 60/103,229, filed October 5, 1998, the contents of which are hereby incorporated by reference.

IN THE CLAIMS

Cancel claims 1 to 30 and 34 to 41, without prejudice or disclaimer. Please amend claims 31 to 33 to recited as follows.

31. (Amended) A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of a peptide consisting of the sequence FLDQVAFXV (Seq. ID No.1) wherein X is any amino acid, under the conditions that induce an immune response to the polypeptide.

32. (Amended) The method of claims 31 or 42, further comprising administering an effective amount of a cytokine to the subject.

33. (Amended) The method of claims 31 or 42, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

Please add new claim 42.

42. (New) A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of a peptide consisting of the sequence FLFSWYAXV (Seq. ID No. 3) wherein X is any amino acid, under the conditions that induce an immune response to the polypeptide.

REMARKS

The subject application is a divisional of U.S. Serial No. 09/249,272, filed February 11, 1999, now allowed. In the parent application, a requirement for restriction was issued. The claims were divided into the following Groups:

- I. Claims 1-12 and 17;
- II. Claims 13-16 and 18-23;
- III. Claims 24-30;

IV. Claims 31-33;

V. Claims 34-39;

VI. Claim 40; and

VII. Claim 41.

Group II was elected and prosecuted in the parent application. Applicant pursues Group IV, claims 31 to 33, in the present application.

Claims 31 to 33 are amended and new claim 42 is added. The claims are amended and new claim 42 is added to conform the relevant claim language to the language of the claims as allowed in the parent application. Page 1 of the specification is amended to update the related application information. An issue of new matter is not raised by these amendments and entry thereof is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Versions with markings to show changes made."** Also attached is a replacement page of claims for the Examiner's convenience. If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned at 650-849-4950.

DATE:

August 1, 2001

Respectfully submitted,

By:

Antoinette F. Konski

Antoinette F. Konski

Registration No.: 34,202

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111
Telephone: (650) 849-4400
Telefax: (650) 849-4800

52054895v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

This application is a divisional of U.S. Serial No. 09/249,272, filed February 11, 1999, now U.S. Patent No. _____, issued _____, which in turn claims priority (under 35 U.S.C. § 119(e)) of U.S. provisional U.S. Application No. 60/103,229, filed October 5, 1998, the contents of which are hereby incorporated by reference.

In the claims:

Cancel claims 1 to 30 and 34 to 41.

Add new claim 42.

31. (Amended) A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of ~~the polypeptide of any one of claims 19-26~~, a peptide consisting of the sequence FLDQVAFXV (Seq. ID No.1) wherein X is any amino acid under the conditions that induce an immune response to the polypeptide.

32. (Amended) The method of ~~claim 31~~ claims 31 or 42, further comprising administering an effective amount of a cytokine to the subject.

33. (Amended) The method of ~~claim 31~~ claims 31 or 42, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

42. (New) A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of a peptide consisting of the sequence FLFSWYAXV (Seq. ID No. 3) wherein X is any amino acid, under the conditions that induce an immune response to the polypeptide.

Pending claims after entry of Preliminary Amendment

31. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of a peptide consisting of the sequence FLDQVAFXV (Seq. ID No.1) wherein X is any amino acid, under the conditions that induce an immune response to the polypeptide.

32. The method of claims 31 or 42, further comprising administering an effective amount of a cytokine to the subject.

33. The method of claims 31 or 42, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

42. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of a peptide consisting of the sequence FLFSWYAXV (Seq. ID No. 3) wherein X is any amino acid, under the conditions that induce an immune response to the polypeptide.